Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Oligodendroglial Lineage Cells in Thyroid Hormone-Deprived Conditions.

Kim MJ, Petratos S.

Stem Cells Int. 2019 Apr 30;2019:5496891. doi: 10.1155/2019/5496891. eCollection 2019. Review.

2.

Limiting neuronal nogo receptor 1 signaling during experimental autoimmune encephalomyelitis (EAE) preserves axonal transport and abrogates inflammatory demyelination.

Lee JY, Kim MJ, Thomas S, Oorschot V, Ramm G, Mun Aui P, Sekine Y, Deliyanti D, Wilkinson-Berka J, Niego B, Harvey AR, Theotokis P, McLean C, Strittmatter SM, Petratos S.

J Neurosci. 2019 May 6. pii: 1760-18. doi: 10.1523/JNEUROSCI.1760-18.2019. [Epub ahead of print]

PMID:
31061088
3.

Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?

Kim MJ, Kang JH, Theotokis P, Grigoriadis N, Petratos S.

Cells. 2018 Dec 20;8(1). pii: E1. doi: 10.3390/cells8010001. Review.

4.

Amyloid-beta-dependent phosphorylation of collapsin response mediator protein-2 dissociates kinesin in Alzheimer's disease.

Mokhtar SH, Kim MJ, Magee KA, Aui PM, Thomas S, Bakhuraysah MM, Alrehaili AA, Lee JY, Steer DL, Kenny R, McLean C, Azari MF, Birpanagos A, Lipiec E, Heraud P, Wood B, Petratos S.

Neural Regen Res. 2018 Jun;13(6):1066-1080. doi: 10.4103/1673-5374.233451.

5.

Nogo receptor expression in microglia/macrophages during experimental autoimmune encephalomyelitis progression.

Alrehaili AA, Lee JY, Bakhuraysah MM, Kim MJ, Aui PM, Magee KA, Petratos S.

Neural Regen Res. 2018 May;13(5):896-907. doi: 10.4103/1673-5374.232488.

6.

Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination.

Lee JY, Kim MJ, Deliyanti D, Azari MF, Rossello F, Costin A, Ramm G, Stanley EG, Elefanty AG, Wilkinson-Berka JL, Petratos S.

EBioMedicine. 2017 Nov;25:122-135. doi: 10.1016/j.ebiom.2017.10.016. Epub 2017 Oct 19.

7.

Nogo receptor 1 regulates Caspr distribution at axo-glial units in the central nervous system.

Lee JY, Kim MJ, Li L, Velumian AA, Aui PM, Fehlings MG, Petratos S.

Sci Rep. 2017 Aug 21;7(1):8958. doi: 10.1038/s41598-017-09405-9.

8.

Blocked, delayed, or obstructed: What causes poor white matter development in intrauterine growth restricted infants?

Tolcos M, Petratos S, Hirst JJ, Wong F, Spencer SJ, Azhan A, Emery B, Walker DW.

Prog Neurobiol. 2017 Jul;154:62-77. doi: 10.1016/j.pneurobio.2017.03.009. Epub 2017 Apr 6. Review.

PMID:
28392287
9.

Thyroid Hormone Signaling in Oligodendrocytes: from Extracellular Transport to Intracellular Signal.

Lee JY, Petratos S.

Mol Neurobiol. 2016 Nov;53(9):6568-6583. doi: 10.1007/s12035-016-0013-1. Epub 2016 Jul 18. Review.

PMID:
27427390
10.

The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.

Dahl LC, Nasa Z, Chung J, Niego B, Tarlac V, Ho H, Galle A, Petratos S, Lee JY, Alderuccio F, Medcalf RL.

PLoS One. 2016 Jul 18;11(7):e0158653. doi: 10.1371/journal.pone.0158653. eCollection 2016.

11.

A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy.

Deliyanti D, Lee JY, Petratos S, Meyer CJ, Ward KW, Wilkinson-Berka JL, de Haan JB.

Clin Sci (Lond). 2016 Aug 1;130(15):1375-87. doi: 10.1042/CS20160068. Epub 2016 Mar 22.

PMID:
27005782
12.

Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?

Bakhuraysah MM, Siatskas C, Petratos S.

Stem Cell Res Ther. 2016 Jan 16;7:12. doi: 10.1186/s13287-015-0272-1. Review.

13.

Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.

Lee JY, Biemond M, Petratos S.

Neurodegener Dis Manag. 2015 Dec;5(6):527-48. doi: 10.2217/nmt.15.50. Epub 2015 Dec 1. Review.

PMID:
26619755
14.

The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption.

Alshehri B, D'Souza DG, Lee JY, Petratos S, Richardson SJ.

J Neuroendocrinol. 2015 May;27(5):303-23. doi: 10.1111/jne.12271. Review.

PMID:
25737004
15.

Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?

Lee JY, Taghian K, Petratos S.

Acta Neuropathol Commun. 2014 Aug 27;2:97. doi: 10.1186/s40478-014-0097-7. Review.

16.

Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells.

Sutinen EM, Korolainen MA, Häyrinen J, Alafuzoff I, Petratos S, Salminen A, Soininen H, Pirttilä T, Ojala JO.

Front Cell Neurosci. 2014 Aug 7;8:214. doi: 10.3389/fncel.2014.00214. eCollection 2014.

17.

The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton.

Mokhtar SH, Bakhuraysah MM, Cram DS, Petratos S.

Int J Alzheimers Dis. 2013;2013:910502. doi: 10.1155/2013/910502. Epub 2013 Dec 12. Review.

18.

Nogo-receptor 1 deficiency has no influence on immune cell repertoire or function during experimental autoimmune encephalomyelitis.

Litwak SA, Payne NL, Campanale N, Ozturk E, Lee JY, Petratos S, Siatskas C, Bakhuraysah M, Bernard CC.

PLoS One. 2013 Dec 5;8(12):e82101. doi: 10.1371/journal.pone.0082101. eCollection 2013.

19.

Human embryonic stem cell-derived oligodendrocytes: protocols and perspectives.

Alsanie WF, Niclis JC, Petratos S.

Stem Cells Dev. 2013 Sep 15;22(18):2459-76. doi: 10.1089/scd.2012.0520. Epub 2013 Jun 12. Review.

20.

Stop CRMPing my style: a new competitive model of CRMP oligomerization.

Petratos S, Lee JY.

J Neurochem. 2013 Jun;125(6):800-2. doi: 10.1111/jnc.12224. Epub 2013 Mar 19. No abstract available.

21.

Multiple sclerosis: does Nogo play a role?

Lee JY, Petratos S.

Neuroscientist. 2013 Aug;19(4):394-408. doi: 10.1177/1073858413477207. Epub 2013 Feb 19. Review.

PMID:
23423307
22.

Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.

Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, Mun Aui P, Siatskas C, Litwak S, Fehlings MG, Strittmatter SM, Bernard CC.

Brain. 2012 Jun;135(Pt 6):1794-818. doi: 10.1093/brain/aws100. Epub 2012 Apr 28.

23.

Phosphorylation and cleavage of the family of collapsin response mediator proteins may play a central role in neurodegeneration after CNS trauma.

Taghian K, Lee JY, Petratos S.

J Neurotrauma. 2012 Jun 10;29(9):1728-35. doi: 10.1089/neu.2011.2063. Epub 2012 Feb 29.

PMID:
22181040
24.

Mesenchymal stem cells for treatment of CNS injury.

Azari MF, Mathias L, Ozturk E, Cram DS, Boyd RL, Petratos S.

Curr Neuropharmacol. 2010 Dec;8(4):316-23. doi: 10.2174/157015910793358204.

25.

Identification of a proline-rich inositol polyphosphate 5-phosphatase (PIPP)•collapsin response mediator protein 2 (CRMP2) complex that regulates neurite elongation.

Astle MV, Ooms LM, Cole AR, Binge LC, Dyson JM, Layton MJ, Petratos S, Sutherland C, Mitchell CA.

J Biol Chem. 2011 Jul 1;286(26):23407-18. doi: 10.1074/jbc.M110.214247. Epub 2011 May 6.

26.

A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases.

Menon KN, Steer DL, Short M, Petratos S, Smith I, Bernard CC.

Mol Cell Proteomics. 2011 Jun;10(6):M110.000042. doi: 10.1074/mcp.M110.000042. Epub 2011 Mar 18.

27.

Novel therapeutic targets for axonal degeneration in multiple sclerosis.

Petratos S, Azari MF, Ozturk E, Papadopoulos R, Bernard CC.

J Neuropathol Exp Neurol. 2010 Apr;69(4):323-34. doi: 10.1097/NEN.0b013e3181d60ddb. Review.

PMID:
20448478
28.

Molecular regulation of Nogo-A in neural cells: Novel insights into structure and function.

Bongiorno D, Petratos S.

Int J Biochem Cell Biol. 2010 Jul;42(7):1072-5. doi: 10.1016/j.biocel.2010.02.007. Epub 2010 Feb 18. Review.

PMID:
20171301
29.

The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism.

Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, Hatzinisiriou I, Maksel D, Aguilar MI, Small DH.

Brain. 2008 Jan;131(Pt 1):90-108. Epub 2007 Nov 13.

PMID:
18000012
30.

Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury.

Azari MF, Profyris C, Karnezis T, Bernard CC, Small DH, Cheema SS, Ozturk E, Hatzinisiriou I, Petratos S.

J Neuropathol Exp Neurol. 2006 Sep;65(9):914-29.

PMID:
16957585
31.

Incomplete Freund's adjuvant enhances locomotor performance following spinal cord injury.

Azari MF, Karnezis T, Bernard CC, Profyris C, LeGrande MR, Zang DW, Cheema SS, Petratos S.

Eur J Neurol. 2005 Dec;12(12):1004-8.

PMID:
16324097
32.

Induction of endogenous neural precursors in mouse models of spinal cord injury and disease.

Azari MF, Profyris C, Zang DW, Petratos S, Cheema SS.

Eur J Neurol. 2005 Aug;12(8):638-48.

PMID:
16053474
33.

TNFalpha mediates Schwann cell death by upregulating p75NTR expression without sustained activation of NFkappaB.

Boyle K, Azari MF, Cheema SS, Petratos S.

Neurobiol Dis. 2005 Nov;20(2):412-27.

PMID:
15905096
34.

Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS.

Azari MF, Profyris C, Le Grande MR, Lopes EC, Hirst J, Petratos S, Cheema SS.

Eur J Neurol. 2005 May;12(5):357-64.

PMID:
15804265
35.

Molecular mechanisms in Schwann cell survival and death during peripheral nerve development, injury and disease.

Boyle K, Azari MF, Profyris C, Petratos S.

Neurotox Res. 2005;7(1-2):151-67. Review.

PMID:
15639806
36.

Expression of the low-affinity neurotrophin receptor, p75(NTR), is upregulated by oligodendroglial progenitors adjacent to the subventricular zone in response to demyelination.

Petratos S, Gonzales MF, Azari MF, Marriott M, Minichiello RA, Shipham KA, Profyris C, Nicolaou A, Boyle K, Cheema SS, Kilpatrick TJ.

Glia. 2004 Oct;48(1):64-75.

PMID:
15326616
37.

Degenerative and regenerative mechanisms governing spinal cord injury.

Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S.

Neurobiol Dis. 2004 Apr;15(3):415-36. Review.

PMID:
15056450
38.

Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice.

Turner BJ, Cheah IK, Macfarlane KJ, Lopes EC, Petratos S, Langford SJ, Cheema SS.

J Neurochem. 2003 Nov;87(3):752-63.

39.

Design and application of a peptide nucleic acid sequence targeting the p75 neurotrophin receptor.

Cheah IK, Cheema SS, Langford SJ, Lopes EC, Macfarlane KJ, Petratos S, Turner BJ.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2377-80.

PMID:
12824038
40.

Schwann cell apoptosis in the postnatal axotomized sciatic nerve is mediated via NGF through the low-affinity neurotrophin receptor.

Petratos S, Butzkueven H, Shipham K, Cooper H, Bucci T, Reid K, Lopes E, Emery B, Cheema SS, Kilpatrick TJ.

J Neuropathol Exp Neurol. 2003 Apr;62(4):398-411.

PMID:
12722832
41.

LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival.

Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ.

Nat Med. 2002 Jun;8(6):613-9.

PMID:
12042813
42.

Neurotrophin receptor expression and responsiveness by postnatal cerebral oligodendroglia.

Starkey GD, Petratos S, Shipham KA, Butzkueven H, Bucci T, Lowry K, Cheema SS, Kilpatrick TJ.

Neuroreport. 2001 Dec 21;12(18):4081-6.

PMID:
11742242
43.

Variable galactocerebroside expression by human Schwann cells in dissociated and peripheral nerve explant cultures.

Turnbull VJ, Petratos S, Papadopoulos R, Gonzales MF, Ayers M.

J Neurosci Res. 2001 Aug 15;65(4):318-21.

PMID:
11494367
44.

Can antiglycolipid antibodies present in HIV-infected individuals induce immune demyelination?

Petratos S, Gonzales ME.

Neuropathology. 2000 Dec;20(4):257-72. Review.

PMID:
11211050
45.

Localization of p450scc and 5alpha-reductase type-2 in the cerebellum of fetal and newborn sheep.

Petratos S, Hirst JJ, Mendis S, Anikijenko P, Walker DW.

Brain Res Dev Brain Res. 2000 Sep 30;123(1):81-6.

PMID:
11020552
46.

Induction of postnatal schwann cell death by the low-affinity neurotrophin receptor in vitro and after axotomy.

Syroid DE, Maycox PJ, Soilu-Hänninen M, Petratos S, Bucci T, Burrola P, Murray S, Cheema S, Lee KF, Lemke G, Kilpatrick TJ.

J Neurosci. 2000 Aug 1;20(15):5741-7.

47.

High-titre IgM anti-sulfatide antibodies in individuals with IgM paraproteinaemia and associated peripheral neuropathy.

Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF.

Immunol Cell Biol. 2000 Apr;78(2):124-32.

PMID:
10762412
48.

High titre anti-sulphatide antibodies in HIV-infected individuals.

Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF.

Neuroreport. 1999 Aug 20;10(12):2557-62.

PMID:
10574369
49.

Peripheral nerve binding patterns of anti-sulphatide antibodies in HIV-infected individuals.

Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF.

Neuroreport. 1999 Jun 3;10(8):1659-64.

PMID:
10501553
50.

Antibodies against peripheral myelin glycolipids in people with HIV infection.

Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF.

Immunol Cell Biol. 1998 Dec;76(6):535-41.

PMID:
9893031

Supplemental Content

Loading ...
Support Center